1. Harrow Inc. (NASDAQ:HROW)
Harrow, Inc. (NASDAQ: HROW) takes the No. 1 position because it already owns a growing portfolio of commercial ophthalmic products instead of relying entirely on an unapproved clinical asset. The company provides exposure to dry-eye disease, surgical eye care, retinal conditions, anesthesia, and other specialized ophthalmology markets supported by aging demographics and rising demand for eye treatment.
Second-quarter 2026 revenue reached $70.7 million, increasing 60% sequentially and 11% year over year. VEVYE generated $29.4 million, rising approximately 40% sequentially and 58% from the previous year. Management maintained full-year revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million.
The acquisition of global rights to TYRVAYA, an FDA-approved nasal spray for dry-eye disease, adds another potentially important product and could deepen Harrow, Inc.’s (NASDAQ: HROW) relationships with ophthalmologists and optometrists. Integration execution, leverage, product concentration, and negative GAAP earnings remain risks, but Harrow, Inc. (NASDAQ: HROW) offers the ranking’s strongest overall combination of established products, prescription growth, expanding revenue, and improving operating leverage.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
